Evidence map›Paper›PMID 41031482›Full record

GuidelineJournal of the European Academy of Dermatology and Venereology : JEADV2026

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F Duarte, Christopher P Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou and 17 more

Abstract readConsensus StatementPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Gandhi DamajCaen University Hospital, Hematology Institute, Normandy University, School of Medicine, Caen, France.
Adèle de MassonDepartment of Dermatology, Saint-Louis Hospital, AP-HP, National Reference Center for Cutaneous Lymphomas, Institut du Cancer AP-HP Nord, Université Paris Cité, Paris, France.ORCID https://orcid.org/0000-0001-7828-6211
Peter DregerDepartment of Medicine V, University of Heidelberg, Heidelberg, Germany.
Ali BazarbachiChair of the EBMT Lymphoma Working Party, Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Philipp BerningDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Rafael F DuarteHospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Christopher P FoxSchool of Medicine, University of Nottingham, Nottingham, UK.
Emmanuella GuenovaUniversity Institute and Clinic for Immuno-Dermatology, Medical Faculty, Johannes Kepler University, Secretary of the EORTC Cutaneous Lymphoma Tumor Group, Linz, Austria.
Olivier HermineService d'Hématologie Adultes, Institut Necker Enfants Malades, Unité INSERM U1153, Hôpital Universitaire Necker-Enfants Malades, AP-HP, Université Paris Cité and Imagine Institute, Paris, France.
Charalampia KyriakouSecretary of the EBMT LWP, Department of Hematology, University College London Hospital, London, UK.
Alina TanaseFundeni Clinical Institute, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Olivier TournilhacDepartment of Hematology and Cell Therapy, Clermont-Ferrand University Hospital, UCA, EA7453 Chelter CIC-1405, Clermont-Ferrand, France.
Wojiech JurczakDepartment of Clinical Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Krakow, Poland.
Imke E KarstenDepartment of Medicine A, University Hospital Münster, Münster, Germany.
Stéphanie Nguyen QuocDepartment of Hematology and Cellular Therapies, Sorbonne University Pitié-Salpêtrière Hospital, Paris, France.
Yasmina SerroukhDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Federico StellaFondazione IRCCS Istituto Nazionale Dei Tumori Milano, University of Milano, Milan, Italy.
Gerald WulfDepartment of Hematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany.
Anna SuredaClinical Hematology Department, Institut Català d'Oncologia - L'hospitalet, Institut de Recerca Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain.
Evangelia PapadavidDepartment of Dermatology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
Pablo L Ortiz-RomeroDepartment of Dermatology Institute i+12, Hospital 12 de Octubre Medical School, University Complutense, Madrid, Spain.
Annalisa RuggeriCo-Chair of the Practice Harmonisation and Guidelines Committee of EBMT and Chair of the CTIWP of the EBMT. Hematology and BMT Unit, IRCCS San Raffaele Hospital, Milan, Italy.
Isabel Sánchez-OrtegaSecretary of the Practice Harmonisation and Guidelines Committee of EBMT; EBMT Medical Officer, Executive Office, Barcelona, Spain.
Julia J ScarisbrickUniversity Hospital Birmingham and University of Birmingham, Birmingham, UK.
Ibrahim Yakoub-AghaChair of the EBMT Practice Harmonisation and Guidelines Committee; Lille University Hospital, Lille University, INSERM U1286, Infinite, Lille, France.
Francesco OnidaCo-Chair of the Practice Harmonisation and Guidelines Committee of the EBMT; Hematology and BMT Centre, ASST Fatebenefratelli-Sacco, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-2991-3474
Norbert SchmitzDepartment of Medicine A, University Hospital Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, T-Cell, CutaneousMycosis FungoidesSezary SyndromeSkin NeoplasmsHumansPatient SelectionTransplantation ConditioningTransplantation, Homologousallogeneic transplantationcutaneous T‐celllymphomasmycosis fungoidesSézary syndromeskin cancer

Identifiers

PMID41031482
PMCPMC12843874

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.